1,355,211 research outputs found
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
No full textBackground: Large observational studies, small prospective studies and post-hoc analyses of randomised clinical trials have suggested that statins could be beneficial in patients with chronic heart failure. However, previous studies have been methodologically weak. We investigated the efficacy and safety of the statin rosuvastatin in patients with heart failure. Methods: We undertook a randomised, double-blind, placebo-controlled trial in 326 cardiology and 31 internal medicine centres in Italy. We enrolled patients aged 18 years or older with chronic heart failure of New York Heart Association class II-IV, irrespective of cause and left ventricular ejection fraction, and randomly assigned them to rosuvastatin 10 mg daily (n=2285) or placebo (n=2289) by a concealed, computerised telephone randomisation system. Patients were followed up for a median of 3·9 years (IQR 3·0-4·4). Primary endpoints were time to death, and time to death or admission to hospital for cardiovascular reasons. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00336336. Findings: We analysed all randomised patients. 657 (29%) patients died from any cause in the rosuvastatin group and 644 (28%) in the placebo group (adjusted hazard ratio [HR] 1·00 [95·5% CI 0·898-1·122], p=0·943). 1305 (57%) patients in the rosuvastatin group and 1283 (56%) in the placebo group died or were admitted to hospital for cardiovascular reasons (adjusted HR 1·01 [99% CI 0·908-1·112], p=0·903). In both groups, gastrointestinal disorders were the most frequent adverse reaction (34 [1%] rosuvastatin group vs 44 [2%] placebo group). Interpretation: Rosuvastatin 10 mg daily did not affect clinical outcomes in patients with chronic heart failure of any cause, in whom the drug was safe. Funding: Società Prodotti Antibiotici (SPA; Italy), Pfizer, Sigma Tau, and AstraZeneca. © 2008 Elsevier Ltd. All rights reserved
Bioinformatics in Italy: BITS 2012, the ninth annual meeting of the Italian Society of Bioinformatics
No full textThe BITS2012 meeting, held in Catania on May 2-4, 2012, brought together almost 100 Italian researchers working in the field of Bioinformatics, as well as students in the same or related disciplines. About 90 original research works were presented either as oral communication or as posters, representing a landscape of Italian current research in bioinformatics.This preface provides a brief overview of the meeting and introduces the manuscripts that were accepted for publication in this supplement, after a strict and careful peer-review by an International board of referees. © 2013 Gissi et al.; licensee BioMed Central Ltd
Silva, I.C.C., Moura, T.M., Gissi, D.S. & Fortuna-Perez, A.P. (2021) A new species of Nissolia Jacq. (Leguminosae, Papilionoideae) from Northern Brazil, recording a new gland type for the genus. Phytotaxa 482 (1): 80-86.
No full textSilva, I.C.C., Moura, T.M., Gissi, D.S., Fortuna-Perez, A.P. (2021): Silva, I.C.C., Moura, T.M., Gissi, D.S. & Fortuna-Perez, A.P. (2021) A new species of Nissolia Jacq. (Leguminosae, Papilionoideae) from Northern Brazil, recording a new gland type for the genus. Phytotaxa 482 (1): 80-86. Phytotaxa 489 (2): 240-240, DOI: https://doi.org/10.11646/phytotaxa.489.2.14, URL: http://dx.doi.org/10.11646/phytotaxa.489.2.1
Planning for climate change: towards adaptive planning and management of the Venitian lagoon
No full textBIARI 1° International Worksho
Potencial de biomassa per energia sostenible mitjançant l'anàlisi de compensació de serveis ecosistèmics: cas d'estudi a Rovigo (Itàlia)
No full textPresentació a càrrec d'Elena Gissi de l'IUAV de Venècia sobre com els serveis ecosistèmics poden incidir en una nova perspectiva de les polítiques energètiques3969.mp4
3969.mp
Le studentesse universitarie: trasformazioni di una figura sociale
No full textNel 1678 Elena Lucrezia Cornaro Piscopia si laurea in Filosofia presso l’Università di Padova. La sua storia è però unica. Per ottenere il libero accesso alle aule universitarie alle donne occorrerà ancora molto tempo: secoli di dibattiti sulle capacità femminili e sulla cosiddetta coeducazione. Possono le donne e gli uomini percorrere gli stessi percorsi di studio, accedere ai medesimi saperi? Ciò costituirebbe una minaccia a ruoli di genere storicamente consolidati? Tra la fine dell’Ottocento e gli inizi del Novecento, la svolta. Alle studentesse è concesso di iscriversi alle università, a Padova come altrove. E lo fanno sempre più numerose e combattive. È ancora il tempo delle pioniere, molte difficoltà continuano a permanere, ma qualcosa è cambiato e il Novecento finirà per essere il secolo delle donne nell’università. Non solo studentesse, dunque, ma anche docenti, portatrici di saperi vecchi e nuovi e desiderose di farli circolare in spazi che fino a quel momento erano stati monopolio maschile. Anche su questo versante, inutile dirlo, il percorso resta irto di ostacoli; lo dimostrano le vicende di molte promettenti ricercatrici costrette a rinunciare ai propri sogni o a prolungare il precariato in luoghi alla periferia dell’accademia. La storia che raccontiamo a partire dall’Ateneo padovano, ma con uno sguardo ampio verso l’Italia e l’Europa, fa luce su una traiettoria fino ad ora assai poco indagata, che ha il suo inizio alla fine del Seicento e come vedremo anche prima. Un percorso accidentato e ben poco lineare, visto che ancora oggi la presenza e il ruolo delle donne nelle università rimane una questione aperta e in buona parte da risolvere
GISSI trial: Early results and late follow-up
No full textIn the GISSI trial, 11,712 patients with acute myocardial infarction were randomized to receive either standard care or standard care with 1.5 million units streptokinase intravenously. A highly significant reduction in mortality during hospitalization in streptokinase-treated patients was observed. The mortality at 1 year was determined in 98.3% of the patients who had been originally randomized; the 1 year mortality of patients discharged alive was similar in those patients treated with streptokinase and those who were not; that is, the beneficial effects of streptokinase treatment on survival that were observed in the hospital phase of the study persisted unchanged and with comparable statistical significance for 1 year. However, a higher incidence of reinfarction occurred in the treated versus the control groups both during the hospital phase and at the 6 month follow-up. Streptokinase treatment had no detectable effect in patients with a history of previous infarction
- …
